MX2020012336A - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
MX2020012336A
MX2020012336A MX2020012336A MX2020012336A MX2020012336A MX 2020012336 A MX2020012336 A MX 2020012336A MX 2020012336 A MX2020012336 A MX 2020012336A MX 2020012336 A MX2020012336 A MX 2020012336A MX 2020012336 A MX2020012336 A MX 2020012336A
Authority
MX
Mexico
Prior art keywords
film
alginate
treatment
pharmaceutical formulation
monovalent cation
Prior art date
Application number
MX2020012336A
Other languages
English (en)
Inventor
Scott Boyer
Fredrik Hübinette
Leif Ingemarsson
Shengzhen Cai
Original Assignee
Klaria Pharma Holding Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaria Pharma Holding Ab filed Critical Klaria Pharma Holding Ab
Publication of MX2020012336A publication Critical patent/MX2020012336A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una película que comprende una sal de alginato de un catión monovalente o una mezcla de sales de alginato que contiene al menos una sal de alginato de un catión monovalente, y un compuesto de la fórmula (I), tal como la adrenalina, o una sal farmacéuticamente aceptable de la misma. La presente invención se refiere además a métodos para fabricar tal película y al uso de tal película en el tratamiento de un paciente humano, en particular al uso de tal película en el tratamiento de una afección seleccionada entre la anafilaxia, la hemorragia superficial y el paro cardíaco.
MX2020012336A 2018-05-23 2019-05-23 Formulacion farmaceutica. MX2020012336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1808462.4A GB201808462D0 (en) 2018-05-23 2018-05-23 Pharmaceutical formulation
PCT/EP2019/063376 WO2019224323A1 (en) 2018-05-23 2019-05-23 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2020012336A true MX2020012336A (es) 2021-01-29

Family

ID=62812324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012336A MX2020012336A (es) 2018-05-23 2019-05-23 Formulacion farmaceutica.

Country Status (12)

Country Link
EP (1) EP3796896A1 (es)
JP (2) JP7419263B2 (es)
KR (1) KR20210031857A (es)
CN (1) CN112236133A (es)
AU (1) AU2019274772A1 (es)
BR (1) BR112020023741A2 (es)
CA (1) CA3098112A1 (es)
GB (1) GB201808462D0 (es)
IL (1) IL278927A (es)
MA (1) MA52704A (es)
MX (1) MX2020012336A (es)
WO (1) WO2019224323A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
SE544672C2 (en) * 2020-05-07 2022-10-11 Liw Innovation Ab New compositions for oral or nasal use
EP4302750A1 (en) * 2022-07-07 2024-01-10 LTS Lohmann Therapie-Systeme AG Oral thin films comprising adrenaline

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933462A (en) * 1958-12-17 1963-08-08 Simone Marie Antoinette Radouc Improvements in or relating to the treatment of meat
US20140271788A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
CA2656961C (en) * 2005-03-15 2014-07-22 Animal Ethics Pty Ltd A topical anaesthetic composition
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
KR100855566B1 (ko) * 2006-09-12 2008-09-03 (주) 아모젠 경구용 소모성 필름
EP2101571B1 (en) * 2006-12-11 2011-05-18 Kempharm, Inc. Ornithine conjugates of amphetamine and processes for making and using the same
KR101077468B1 (ko) * 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
KR101303479B1 (ko) * 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제
EP2739140A4 (en) * 2011-07-29 2015-06-03 Shire Llc PRODRUGS OF HOMOARGININE AND / OR CONJUGATES OF AMPHETAMINES AND OTHER STIMULANTS AND METHODS OF MAKING AND USING SAME
CN102961365B (zh) * 2012-12-17 2016-01-20 天津市聚星康华医药科技有限公司 硫酸特布他林口腔速溶膜及其制备方法
WO2014137189A1 (ko) * 2013-03-07 2014-09-12 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법
WO2014202088A1 (en) * 2013-06-17 2014-12-24 Rigshospitalet Injectable pharmaceutical compositions comprising adrenaline and citric acid
US20160303040A1 (en) * 2013-11-19 2016-10-20 Rigshospitalet Injectable pharmaceutical compositions comprising prostacyclin
WO2017135195A1 (ja) * 2016-02-03 2017-08-10 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤

Also Published As

Publication number Publication date
IL278927A (en) 2021-01-31
CN112236133A (zh) 2021-01-15
EP3796896A1 (en) 2021-03-31
GB201808462D0 (en) 2018-07-11
JP2021526519A (ja) 2021-10-07
MA52704A (fr) 2021-03-31
AU2019274772A1 (en) 2020-11-19
KR20210031857A (ko) 2021-03-23
CA3098112A1 (en) 2019-11-28
BR112020023741A2 (pt) 2021-02-09
US20210369601A1 (en) 2021-12-02
JP7419263B2 (ja) 2024-01-22
JP2024050598A (ja) 2024-04-10
WO2019224323A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2020012041A (es) Formulacion farmaceutica.
NZ739211A (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PH12017501939B1 (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
NZ740429A (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2020012336A (es) Formulacion farmaceutica.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
PH12016501357B1 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX2019012884A (es) Terapia de combinacion.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
TN2015000386A1 (en) Formulations of organic compounds
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
BR112015024897A2 (pt) derivado de fenila
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
MY197042A (en) Compounds
PL423672A1 (pl) Kompozycja farmaceutyczna zawierająca zebularynę oraz środek leczniczy do regeneracji ran
PH12020551620A1 (en) Compositions for preventing or treating dry eye